<DOC>
	<DOCNO>NCT02232360</DOCNO>
	<brief_summary>The purpose study determine effect combination therapy rosuvastatin fenofibrate atheromatous plaque tissue characteristic de novo coronary lesion intermediate stenosis patient coronary artery disease , compare rosuvastatin alone therapy .</brief_summary>
	<brief_title>Effects Combined Therapy With Statin Plus Fenofibrate Coronary Atherosclerotic Plaque Compared With Statin Alone</brief_title>
	<detailed_description>Cardiovascular disease remain leading cause morbidity mortality worldwide . In past decade , optimal pharmacological therapy statins target LDL-cholesterol substantially reduce risk cardiovascular disease . However , residual cardiovascular risk still high , require need additional preventive therapy achieve even great risk reduction . Recent meta-analysis demonstrate fibrates reduce risk coronary event might role patient high cardiovascular risk combine dyslipidemia . Likewise , fenofibrate possible benefit patient high triglyceride level low HDL-cholesterol level post-hoc analysis ACCORD FIELD trial . Thus , investigator try determine effect combination therapy rosuvastatin fenofibrate atheromatous plaque tissue characteristic de novo coronary lesion intermediate stenosis patient coronary artery disease , compare rosuvastatin alone therapy .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Plaque , Atherosclerotic</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Patients coronary artery disease 20 year age old need coronary angiography Intermediate coronary artery stenosis ( diameter stenosis ≥30 % ≤60 % visual estimation , diameter ≥2.0 mm ≤4.0 mm , de novo lesion native coronary artery ) virtual histologyintravascular ultrasound ( VHIVUS ) could feasible Combined dyslipidemia Stainnaive patient LDLcholesterol ≥70 mg/dL nonHDLcholesterol ≥130 mg/dL Patients take statin within 2 week LDLcholesterol &lt; 100 mg/dL nonHDLcholesterol ≥130 mg/dL Patients give write informed consent Diabetic patient Cardiogenic shock Heart failure symptoms New York Heart Association class III/IV leave ventricular ejection fraction &lt; 35 % Renal dysfunction ( creatinine level ≥1.7 mg/dL dependence dialysis Hepatic dysfunction ( transaminase level &gt; 3 time normal within limit ) Pregnancy breastfeed woman Familial hypercholesterolemia Hypertriglyceridemia ( triglyceride level &gt; 500 mg/dL )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Atherosclerotic plaque</keyword>
	<keyword>Virtual histology intravascular ultrasound</keyword>
	<keyword>Plaque composition</keyword>
	<keyword>Rosuvastatin</keyword>
	<keyword>Fenofibrate</keyword>
	<keyword>Coronary artery disease</keyword>
</DOC>